Some three years after the University of Pennsylvania claimed four of Roche’s breast cancer meds infringed its intellectual ...

Ann Marie Rogers won a landmark victory to make the breast cancer drug Herceptin more widely available. Here, she explains what drove her. But others are asking if the treatment really lives up to ...

The research, which comes from several groups including Genentech, makers of the prevailing anti-HER2 treatment, has researchers questioning ... By the late ’90s, a drug called Herceptin that targeted ...

Cancer research saved my daughter’s life, and despite setbacks, we must support these efforts to ensure more lives are saved ...

The PD-1 checkpoint inhibitor cancer treatment is fast becoming the backbone ... biosimilar launch in Europe is a version of Roche’s Herceptin (trastuzumab). Biosimilar companies are poised ...

The latest Herceptin biosimilar is branded as Kanjinti (trastuzumab-anns) and is approved in all indications of the reference product. These are for the treatment of HER2-overexpressing adjuvant ...

In the small group of study patients at M.D. Anderson who received Herceptin, says Buzdar, none so far has developed any heart problems almost two years after treatment. Some doctors have ...

Do not stop your Herceptin SC treatment without talking to your doctor first. Do not take any other medicines, whether they require a prescription or not, without first telling your doctor or ...

versus Perjeta plus Herceptin for SC and optional physician's choice of endocrine therapy as a maintenance treatment in HER2-positive disease. Roche currently carries a Zacks Rank #4 (Sell).

Herceptin is one of a new class of drugs called monoclonal antibodies -- lab-engineered antibodies designed to mimic the body's own immune system response. Herceptin targets the HER2 protein ...

This crisis has been worsened by the transition from the NHIF to the Social Health Authority (SHA), which has caused widespread disruptions in healthcare services. Be part of an exclusive group of ...